DAFODIL: A novel liposome-encapsulated synergistic combination of doxorubicin and 5FU for low dose chemotherapy

PEGylated liposomes have transformed chemotherapeutic use of doxorubicin by reducing its cardiotoxicity; however, it remains unclear whether liposomal doxorubicin is therapeutically superior to free doxorubicin. Here, we demonstrate a novel PEGylated liposome system, named DAFODIL (Doxorubicin And 5...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Control Release
Päätekijät: Camacho, Kathryn M., Menegatti, Stefano, Vogus, Douglas R., Pusuluri, Anusha, Fuchs, Zoë, Jarvis, Maria, Zakrewsky, Michael, Evans, Michael A., Chen, Renwei, Mitragotri, Samir
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2016
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5289372/
https://ncbi.nlm.nih.gov/pubmed/27034194
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jconrel.2016.03.027
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia